J. Roth

发表

“Weighing in” on synergy: Preclinical research on neurohormonal anti-obesity combinations

D. Parkes, J. Trevaskis, J. Roth, 2010, Brain Research.

Melanocortin receptor signaling through mitogen-activated protein kinase in vitro and in rat hypothalamus

D. Daniels, S. Fluharty, J. Roth, 2003, Brain Research.

Modeling the pathways of energy balance using the N1E-115 murine neuroblastoma cell line.

S. Fluharty, J. Roth, D. K. Yee, 2002, Brain research. Molecular brain research.

Interaction of Leptin and Amylin in the Long‐term Maintenance of Weight Loss in Diet‐induced Obese Rats

C. Weyer, D. Parkes, J. Koda, 2010, Obesity.

Insights into amylin–leptin synergy

D. Parkes, J. Trevaskis, J. Roth, 2010, Trends in Endocrinology & Metabolism.

Glucagon-like peptide-1 receptor agonism improves metabolic, biochemical, and histopathological indices of nonalcoholic steatohepatitis in mice.

B. Neuschwander‐Tetri, D. Parkes, E. Brunt, 2012, American journal of physiology. Gastrointestinal and liver physiology.

Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH

J. Jelsing, N. Vrang, L. Adorini, 2019, BMC Gastroenterology.

Integrated Neurohormonal Approach to the Treatment of Obesity: The Amylin Agonist Pramlintide and Its Interactions with Leptin and PYY Signaling Pathways

C. Weyer, D. Parkes, C. Mack, 2008 .

Comparison of either norepinephrine-uptake inhibitors or phentermine combined with serotonergic agents on food intake in rats

N. Rowland, J. Roth, M. Marshall, 2000, Psychopharmacology.

Anorectic efficacy of the fenfluramine/phentermine combination in rats: additivity or synergy?

N. Rowland, J. Roth, Neil E. Rowland, 1999, European journal of pharmacology.

Effects of obeticholic acid on lipoprotein metabolism in healthy volunteers

R. Pencek, J. Roth, R. Hooshmand-Rad, 2016, Diabetes, obesity & metabolism.

Amylin/leptin synergy is absent in extreme obesity and not restored by calorie restriction‐induced weight loss in rats

D. Parkes, J. Trevaskis, J. Roth, 2016, Obesity science & practice.

Davalintide (AC2307), a novel amylin-mimetic peptide: enhanced pharmacological properties over native amylin to reduce food intake and body weight

B. Roland, Soumitra S Ghosh, S. Adams, 2010, International Journal of Obesity.

Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment.

Soumitra S Ghosh, J. Herich, J. Heilig, 2013, American journal of physiology. Gastrointestinal and liver physiology.

Pharmacological actions of the peptide hormone amylin in the long-term regulation of food intake, food preference, and body weight.

K. Laugero, D. Parkes, J. Reynolds, 2007, American journal of physiology. Regulatory, integrative and comparative physiology.

Simultaneous quantification of the glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) receptor agonists in rodent plasma by on-line solid phase extraction and LC-MS/MS.

Steven W. Taylor, J. Roth, Yan Wang, 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Interactions of amylinergic and melanocortinergic systems in the control of food intake and body weight in rodents

C. Jodka, D. Parkes, J. Hoyt, 2012, Diabetes, obesity & metabolism.

Of Mice and Men: Translational Research on Amylin Agonism

D. Parkes, C. Mack, J. Trevaskis, 2011 .

Multi-hormonal weight loss combinations in diet-induced obese rats: Therapeutic potential of cholecystokinin?

D. Parkes, J. Trevaskis, J. Roth, 2010, Physiology & Behavior.

Amylin-mediated restoration of leptin responsiveness in diet-induced obesity: magnitude and mechanisms.

C. Weyer, A. Baron, B. Walsh, 2008, Endocrinology.

Role of islet-, gut-, and adipocyte-derived hormones in the central control of food intake and body weight: implications for an integrated neurohormonal approach to obesity pharmacotherapy.

C. Weyer, Hubert C. Chen, B. E. Schroeder, 2008, Current diabetes reviews.

Amylin and the regulation of appetite and adiposity: recent advances in receptor signaling, neurobiology and pharmacology

J. Roth, 2013, Current opinion in endocrinology, diabetes, and obesity.

It Takes Two to Tango

J. Chan, C. Weyer, J. Roth, 2009, Journal of Investigative Medicine.

Combination therapy with amylin and peptide YY[3-36] in obese rodents: anorexigenic synergy and weight loss additivity.

C. Weyer, C. Jodka, D. Parkes, 2007, Endocrinology.

Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression.

C. Anderson, A. Baron, Eric S. Kendall, 2006, Endocrinology.

Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications.

B. Roland, Steve Chen, J. Roth, 2009, Archives of neurology.

Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy.

J. Jelsing, N. Vrang, J. Roth, 2016, World journal of hepatology.

Antiobesity effects of the β-cell hormone amylin in combination with phentermine or sibutramine in diet-induced obese rats

C. Weyer, D. Parkes, C. Mack, 2008, International Journal of Obesity.

Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression.

C. Anderson, A. Baron, Eric S. Kendall, 2006, Endocrinology.

Amylin: Pharmacology, Physiology, and Clinical Potential

D. Hay, D. Parkes, T. Lutz, 2015, Pharmacological Reviews.

Effects of l-Arginine on Angiotensin II-Related Water and Salt Intakes

N. Rowland, J. Roth, 1998, Physiology & Behavior.

Hormone-based therapies in the regulation of fuel metabolism and body weight

D. Maggs, J. Roth, N. Kesty, 2008, Expert opinion on biological therapy.

Leptin responsiveness restored by amylin agonism in diet-induced obesity: Evidence from nonclinical and clinical studies

Christian Weyer, B. Roland, C. Anderson, 2008, Proceedings of the National Academy of Sciences.

Noradrenergic neurons of the area postrema mediate amylin's hypophagic action.

B. Roland, T. Lutz, J. Roth, 2010, American journal of physiology. Regulatory, integrative and comparative physiology.

Effects of prior or concurrent food restriction on amylin-induced changes in body weight and body composition in high-fat-fed female rats.

C. Anderson, J. Trevaskis, J. Roth, 2007, American journal of physiology. Endocrinology and metabolism.

Interactive Effects of Neurochemicals on Ingestive Behavior

N. Rowland, J. Roth, 2000, Nutritional neuroscience.

Mechanisms of amylin/leptin synergy in rodent models.

D. Parkes, B. Levin, J. Trevaskis, 2010, Endocrinology.

FXR activation by obeticholic acid or nonsteroidal agonists induces a human-like lipoprotein cholesterol change in mice with humanized chimeric liver[S]

Jingwen Liu, Xueqing Liu, R. Papazyan, 2018, Journal of Lipid Research.

INT-767 improves histopathological features in a diet-induced ob/ob mouse model of biopsy-confirmed non-alcoholic steatohepatitis

J. Jelsing, N. Vrang, Kristoffer T. G. Rigbolt, 2018, World journal of gastroenterology.

Enhanced amylin-mediated body weight loss in estradiol-deficient diet-induced obese rats.

D. Parkes, J. Reynolds, C. Mack, 2010, Endocrinology.

Dexfenfluramine and norfenfluramine: comparison of mechanism of action in feeding and brain Fos-ir studies.

N. Rowland, M. McMullen, J. Roth, 2000, American journal of physiology. Regulatory, integrative and comparative physiology.

Efficacy of administration of dexfenfluramine and phentermine, alone and in combination, on ingestive behavior and body weight in rats

N. Rowland, J. Roth, Neil E. Rowland, 1998, Psychopharmacology.

Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.

D. Parkes, Jason R. Clapper, L. D’Souza, 2013, European journal of pharmacology.

GLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities

D. Parkes, M. Erickson, Jonathan D Roth, 2012, British journal of pharmacology.

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

J. Jelsing, N. Vrang, L. Adorini, 2019, Scientific Reports.

Combined obeticholic acid and elafibranor treatment promotes additive liver histological improvements in a diet-induced ob/ob mouse model of biopsy-confirmed NASH

J. Jelsing, N. Vrang, L. Adorini, 2019, Scientific Reports.

Implications of amylin receptor agonism: integrated neurohormonal mechanisms and therapeutic applications.

B. Roland, Steve Chen, J. Roth, 2009, Archives of neurology.

Themed Section: Secretin Family (Class B) G Protein-Coupled Receptors – from Molecular to Clinical Perspectives

M. Erickson, Steve Chen, J. Roth, 2012 .

Simultaneous quantification of the glucagon-like peptide-1 (GLP-1) and cholecystokinin (CCK) receptor agonists in rodent plasma by on-line solid phase extraction and LC-MS/MS.

Steven W. Taylor, J. Roth, Yan Wang, 2014, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.

Amylin-Based Pharmacotherapy - Past, Present & Future

Soumitra S Ghosh, D. Parkes, C. Mack, 2008 .

Effects of amylin and bupropion/naltrexone on food intake and body weight are interactive in rodent models.

D. Parkes, Jason R. Clapper, J. Roth, 2013, European journal of pharmacology.